Andrew Funderburk is a Vice President at Health Advances, LLC. Since joining the firm in 2005, Andrew has led dozens of projects for biopharma clients. He has particular expertise in helping companies formulate clinical development, commercialization, and lifecycle management strategies to maximize the value of therapeutics. He has worked extensively on commercialization issues related to orphan drugs for companies ranging from VC-backed biotechs to multinational pharmaceuticals. Prior to Health Advances, Andrew worked with Michael Porter of the Harvard Business School on business strategy and healthcare policy, and with Monitor Group and Genentech. Andrew earned an AB in Economics from Princeton University, and an MBA from the Harvard Business School.